改良移植后环磷酰胺对比粒细胞集落刺激因子/抗胸腺细胞球蛋白方案在重型再生障碍性贫血替代供者移植中的临床结局
本研究比较改良移植后环磷酰胺(mPTCy)与粒细胞集落刺激因子/抗胸腺细胞球蛋白(G-CSF/ATG)方案在重型再生障碍性贫血替代供者造血干细胞移植中的结局。mPTCy方案为ATG 2.0 mg/kg/天(第-5至-3天)联合环磷酰胺40 mg/kg/天(第+3和+4天)。多因素分析显示mPTCy组100天II-IV度急性GVHD(HR 0.43,95%CI 0.26-0.71,p<0.001)、2年慢性GVHD(HR 0.33,95%CI 0.17-0.65,p=0.001)风险降低,2年GRFS改善(HR 0.51,95%CI 0.32-0.83,p=0.007)。亚组分析显示单倍体移植中mPTCy结局更优,无关供者移植两方案相当。
要点
- mPTCy方案降低100天II-IV度急性GVHD风险(HR 0.43,95%CI 0.26-0.71,p<0.001)。
- mPTCy方案降低2年慢性GVHD风险(HR 0.33,95%CI 0.17-0.65,p=0.001)并改善2年GRFS(HR 0.51,95%CI 0.32-0.83,p=0.007)。
- 单倍体移植中mPTCy结局更优,无关供者移植两方案结局相当。
核心结论
- 在重型再生障碍性贫血替代供者造血干细胞移植中,mPTCy较G-CSF/ATG降低GVHD风险并改善GRFS,尤其在单倍体移植中。
研究设计与样本
- 事后比较分析,利用前瞻性mPTCy队列(ChiCTR2000038297,n=101,另加1年方案一致性入组扩展n=56)与回顾性历史G-CSF/ATG队列(n=140)比较替代供者造血干细胞移植结局。
- mPTCy方案为ATG 2.0 mg/kg/天(第-5至-3天)联合环磷酰胺40 mg/kg/天(第+3和+4天)。
主要发现
- 两方案植入率、植入失败率和总生存率相似。
- 多因素分析显示mPTCy较G-CSF/ATG降低100天II-IV度急性GVHD风险(HR 0.43,95%CI 0.26-0.71,p<0.001)。
- mPTCy较G-CSF/ATG降低2年慢性GVHD风险(HR 0.33,95%CI 0.17-0.65,p=0.001)。
- mPTCy较G-CSF/ATG改善2年GVHD无复发生存/无排斥生存(GRFS;HR 0.51,95%CI 0.32-0.83,p=0.007)。
- 亚组分析显示单倍体移植中mPTCy结局更优,无关供者移植两方案结局相当。
关键数值与推荐
- mPTCy方案:ATG 2.0 mg/kg/天(第-5至-3天),环磷酰胺40 mg/kg/天(第+3和+4天)。
- 100天II-IV度急性GVHD:mPTCy vs G-CSF/ATG的HR 0.43(95%CI 0.26-0.71,p<0.001)。
- 2年慢性GVHD:mPTCy vs G-CSF/ATG的HR 0.33(95%CI 0.17-0.65,p=0.001)。
- 2年GRFS:mPTCy vs G-CSF/ATG的HR 0.51(95%CI 0.32-0.83,p=0.007)。
临床怎么用
- 作者认为,在重型再生障碍性贫血替代供者造血干细胞移植中,mPTCy较G-CSF/ATG降低GVHD并改善GRFS,尤其在单倍体移植中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Post-transplantation cyclophosphamide (PTCy) and granulocyte colony-stimulating factor/anti-thymocyte globulin (G-CSF/ATG) are established protocols for alternative donor haematopoietic stem cell transplantation (AD-HSCT) in severe aplastic anaemia (SAA). A modified PTCy (mPTCy) regimen, featuring increased ATG dosing (2.0 mg/kg/day, days -5 to -3) and reduced cyclophosphamide (40 mg/kg/day, days +3 and +4), showed promising outcomes in a prospective study but lacks direct comparison with G-CSF/ATG. This post hoc comparative analysis utilized data from our prospective mPTCy cohort (ChiCTR2000038297, n = 101, plus a 1-year protocol-consistent enrolment extension, n = 56) and a retrospective historical G-CSF/ATG cohort (n = 140) to compare outcomes in AD-HSCT. Both protocols showed similar incidences of engraftment, graft failure and overall survival. Multivariate analysis confirmed reduced risks of 100-day grade II-IV acute graft-versus-host disease (GVHD) (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.26-0.71, p < 0.001) and 2-year chronic GVHD (HR 0.33, 95% CI 0.17-0.65, p = 0.001), and improved 2-year GVHD, relapse/rejection-free survival (GRFS; HR 0.51, 95% CI 0.32-0.83, p = 0.007) with mPTCy versus G-CSF/ATG. Subgroup analysis revealed superior outcomes with mPTCy in haploidentical-HSCT, while outcomes were comparable between protocols in unrelated donor HSCT. These findings suggest mPTCy superiority over G-CSF/ATG in SAA patients undergoing AD-HSCT, especially haploidentical-HSCT, by reducing GVHD and improving GRFS.
引用
- Wu L, Zhou M, Chen X, et al. Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia. Br J Haematol. 2025. PMID: 40947584. doi:10.1111/bjh.70133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。